â??Effect of activated charcoal on reduction of bilrubin levels in patients with obstructive jaundice due to cancer and undergoing stenting to relieve the obstruction"

Oral activated charcoal to hasten reduction of bilirubin after endoscopic stenting of malignant biliary obstruction â?? A phase-2, single-arm, single-stage trial.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/12/048480

Enrollment

Registered

2022-12-26

Start date

Unknown

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K87- Disorders of gallbladder, biliarytract and pancreas in diseases classified elsewhere

Interventions

Intervention1: Oral activated charcoal: Oral activated charcoal at a dose of 1gm thrice daily to be given to patients who are undergoing biliary stenting for malignant biliary obstruction and see the

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age more than 18 year 2. Diagnosed to have malignant biliary obstruction 3. With bilirubin more than 10 mg% 4. Either planned for surgery or neoadjuvant chemotherapy 5. Undergoing endoscopic biliary stenting

Exclusion criteria

Exclusion criteria: 1. Age less than 18 years 2. Biliary obstruction other than malignancy related 3. Bilirubin less than 10 mg% 4. ECOG 3-4 5. Those undergoing palliative stenting

Design outcomes

Primary

Measure	Time frame
To assess the proportion of patients who have a bilirubin of 3 mg% or less after 2 weeks of biliary stenting and are given oral activated charcoal.Timepoint: At the end of 2 weeks of charcoal therapy	—

Secondary

Measure	Time frame
To assess the safety of charcoal in patients with malignant biliary obstruction.Timepoint: At the end of 2 weeks of charcoal therapy	—

Countries

India

Contacts

Public ContactDr Vijay Balaji M

Christian Medical College

sudiptadharchowdhury@gmail.com9952311988

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026